In the past few years, some high-profile dividend stocks have reduced their payouts, much to the chagrin of investors. As ...

Medical device and healthcare company Abbott has opened a new facility in Kilkenny, which is expected to employ 800 people.

Argus analyst David Toung raised the firm’s price target on Abbott (ABT) to $150 from $145 and keeps a Buy rating on the shares. Abbott’s ...

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and ...

Global healthcare leader Abbott has developed Ensure Gold, a science-based nutrition solution available in both powder and ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, ...

Abbott Laboratories (NYSE: ABT) is a well-diversified health care company, with four distinct units: medical devices, ...

A few weeks ago, an allergist prescribed a two-week course of an oral steroid to clear up my sinus inflammation. Before I ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes Care and Medical Devices.